Drug developer NuPathe (PATH) is down 51.5% premarket after announcing the FDA has rejected its...

|By:, SA News Editor

Drug developer NuPathe (PATH) is down 51.5% premarket after announcing the FDA has rejected its Zeltrix migraine patch, due to "chemistry, manufacturing, and safety questions." NuPathe had planned to launch Zeltrix in 1H 2012.